Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks [Yahoo! Finance]
Kodiak Sciences Inc (KOD)
Last kodiak sciences inc earnings: 11/12 05:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The company's proprietary antibody biopolymer conjugate platform is designed to maintain potent and effective drug levels in ocular tissues for longer periods than the currently marketed biologic medicines for treating retinal diseases. The company currently has no marketed drug in its portfolio. It is developing its lead investigational candidate, tarcocimab, a novel anti-VEGF antibody biopolymer conjugate, for the treatment of retinal vascular diseases. Such diseases include diabetic eye disease and wet age-related macular degeneration (wet AMD). In late 2023, Kodiak decided to reboot its tarcocimab development program after witnessing positive top-line results from its phase III GLOW1 study evaluating the same in moderately severe to severe non-proliferative diabetic retinopathy (NPDR). In 2023, the company faced a major developmental setback that led to the abandonment of the development program of its lead candidate, tarcocimab, in the treatment of retinal vascular diseas
Show less
Read more
Impact Snapshot
Event Time:
KOD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KOD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KOD alerts
High impacting Kodiak Sciences Inc news events
Weekly update
A roundup of the hottest topics
KOD
News
- Will Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely? [Yahoo! Finance]Yahoo! Finance
- Corneal Edema Therapeutics Market to Grow Significantly at a CAGR of 8.54% in the US by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Kodiak Sciences Inc. (NASDAQ: KOD) had its price target raised by analysts at UBS Group AG from $3.00 to $5.00. They now have a "neutral" rating on the stock.MarketBeat
- Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
KOD
Earnings
- 3/28/24 - Miss
KOD
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- KOD's page on the SEC website